Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays
暂无分享,去创建一个
Els Brouwers | Nick Geukens | Thomas Van Stappen | Ann Gils | S. Vermeire | T. Van Stappen | A. Gils | P. Declerck | S. Tops | E. Brouwers | Séverine Vermeire | N. Geukens | Sophie Tops | Paul J. Declerck
[1] L. A. Christensen,et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.
[2] Ann Gils,et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial , 2012 .
[3] S. Vermeire,et al. Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays , 2012, Alimentary pharmacology & therapeutics.
[4] M. Silverberg,et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] C. Milstein,et al. [1] Preparation of monoclonal antibodies: Strategies and procedures , 1981 .
[6] S. Ben-Horin,et al. Review article: loss of response to anti‐TNF treatments in Crohn’s disease , 2011, Alimentary pharmacology & therapeutics.
[7] S. Hanauer,et al. Assessing Response and Loss of Response to Biological Therapies in IBD , 2011, The American Journal of Gastroenterology.
[8] C. Milstein,et al. Preparation of monoclonal antibodies: strategies and procedures. , 1981, Methods in enzymology.
[9] A. Cheifetz,et al. Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis , 2013, The American Journal of Gastroenterology.
[10] P. Rutgeerts,et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial , 2011, Gut.
[11] M. Silverberg,et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.
[12] S. Vermeire,et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. , 2010, Journal of Crohn's & colitis.
[13] G Van Assche,et al. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment , 2011, Gut.
[14] C. Wagner,et al. Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] T. Klausen,et al. Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohn's Disease , 2013, Therapeutic drug monitoring.
[16] Dietmar Stöckl,et al. Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. , 2002, Clinical chemistry.
[17] Paul Rutgeerts,et al. Biological therapies for inflammatory bowel diseases. , 2009, Gastroenterology.
[18] P. Rutgeerts,et al. 1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial , 2012 .
[19] A. Gils,et al. Importance of the Hinge Region between α-Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies* , 2000, The Journal of Biological Chemistry.
[20] Els Brouwers,et al. Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization , 2014, Therapeutic drug monitoring.
[21] P. Nakane,et al. PEROXIDASE-LABELED ANTIBODY A NEW METHOD OF CONJUGATION , 1974, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.